Abstract
Osteonecrosis of the jaw is considered one of the complicated side effects of antiresorptive medications. Such patients are at higher risk to bisphosphonate-related osteonecrosis of the jaw (BRONJ) following implant placement, due to the suppressive effect of such medications on angiogenesis and osteogenesis. Conservative treatment of such disease includes the use of different biological mediators like Leukocyte-platelet rich fibrin (L-PRF) and concentrated growth factor (CGF).